✓ Medically reviewed✍️ HairBase editorial team📅 Last updated: June 14, 2026⏱ 1 min read
💡 Quick answer
Limited evidence. Saw palmetto may weakly block DHT, and small studies show modest benefit — but it's far less effective than finasteride. A mild, natural option for those avoiding prescription drugs.
As an AliExpress affiliate, we may earn a commission from qualifying purchases.
Evidence: Limited
Limited evidence — saw palmetto is a weak natural DHT-blocker with modest results in small studies, far below finasteride.
Saw palmetto is thought to inhibit 5-alpha-reductase (the enzyme that makes DHT), the same target as finasteride — but far more weakly. Small trials, oral and topical, show some men get a modest improvement or slower loss. The studies are limited in size and quality, and head-to-head it doesn't approach finasteride's effect.
Bottom line: saw palmetto is a reasonable, lower-potency option if you specifically want to avoid prescription anti-androgens and accept smaller results. It's not risk-free (mild stomach upset, hormonal effects) — check with a doctor, especially if combining with other treatments, and don't expect finasteride-level regrowth.
2002First randomized, double-blind, placebo-controlled trial of botanical 5-alpha-reductase inhibitors (liposterolic saw palmetto extract + beta-sitosterol) for androgenetic alopecia published (Prager et al., J Altern Complement Med 2002;8(2):143-52) — established proof-of-concept for botanical DHT inhibition in pattern hair loss.
2012First long-term (2-year/24-month) head-to-head comparison of Serenoa repens 320 mg vs finasteride 1 mg in 100 men with AGA (Rossi et al., Int J Immunopathol Pharmacol 2012), an open-label active-comparator study showing saw palmetto is markedly weaker than finasteride (38% vs 68% improved).
2020First dedicated systematic review of saw palmetto for alopecia (Evron et al., Skin Appendage Disord 2020;6(6):329-337) pooling 5 RCTs + 2 cohorts; concluded effects are positive but evidence is low-quality, with small samples and confounded combination products.
2023Modern standardized 16-week, four-arm RCT of oral and topical saw palmetto oil (VISPO) in 80 subjects (Sudeep et al., Clin Cosmet Investig Dermatol, Nov 2023) demonstrating measurable hair-fall reduction, density gain, and serum DHT reduction versus placebo.
Key clinical studies
Prager et al., 20022002
Randomized, double-blind, placebo-controlled pilot RCT; active arm of 10 men (ages 23-64) with mild-to-moderate AGA (some secondary sources cite 26 men total randomized; abstract emphasizes the 10-man active arm)
60% (6/10) of men taking oral saw palmetto plus beta-sitosterol were rated 'improved' by blinded investigators vs ~11% on placebo. Small pilot; established proof-of-concept but cannot support firm efficacy conclusions.
Randomized open-label active-comparator trial; 100 men with mild-to-moderate AGA, 24 months
Hair growth increased in 38% of the Serenoa repens 320 mg/day group vs 68% of the finasteride 1 mg/day group; saw palmetto acted mainly on the vertex while finasteride improved both vertex and frontal areas — saw palmetto clearly less effective than finasteride.
International Journal of Immunopathology and Pharmacology (Int J Immunopathol Pharmacol 2012;25(4):1167-73)
Evron et al., 2020 (systematic review)2020
Systematic review of 7 studies (5 RCTs + 2 prospective cohorts) of oral/topical saw palmetto (100-320 mg) in AGA and telogen effluvium
Across pooled studies: ~60% improvement in overall hair quality, 27% increase in total hair count, increased density in 83.3% of patients, and disease stabilization in 52%. Authors stress evidence is low-quality with small samples, no standardization, and confounding from combination formulations.
Oral saw palmetto reduced hair fall by up to ~29% and increased hair density ~5.17%; topical reduced hair fall ~22% and increased density ~7.61%, with a marked reduction in serum DHT versus placebo and no serious adverse effects.
Clinical, Cosmetic and Investigational Dermatology (Clin Cosmet Investig Dermatol 2023)
Latest research: Recent 2023-2026 work has shifted from crude extracts to standardized, bioactive-fatty-acid saw palmetto formulations (e.g., VISPO and proprietary Serenoa repens extracts) tested in placebo-controlled trials with objective endpoints (phototrichograms, serum DHT) and increasingly in adults with self-perceived thinning hair, alongside network meta-analyses benchmarking it against minoxidil and finasteride. The consensus remains that saw palmetto is a low-risk but modestly effective, lower-evidence option, far weaker than finasteride and best viewed as adjunctive rather than first-line therapy.
Summaries reflect published, peer-reviewed research and are not medical advice. See the linked sources for details.
No. It targets the same DHT pathway but much more weakly, with smaller and less consistent results. It's an alternative for people avoiding prescription drugs, not an equal substitute.
Should I take saw palmetto orally or use it topically?
Both have been studied with modest results. Oral has more hormonal reach (and potential side-effects); topical is gentler. Evidence doesn't strongly favour one — discuss with a doctor if you have hormone-sensitive conditions.
Not medical advice. General education only; it does not replace diagnosis or treatment by a licensed professional. Consult a board-certified dermatologist before starting, stopping or changing any treatment.